Human Leukopaks

All filters

Condition

Condition

Condition

Start typing to see matching condition.

Most stocked

Format

Format

Format
Volume

Volume

Volume
Donor Demographics

Donor Demographics

Gender
Age
Race

Start typing to see matching race.

Country
Medical History

Medical History

Medications

Start typing to see matching medications.

Comorbidities

Start typing to see matching comorbidities.

Allergy List

Start typing to see matching allergy list.

Lab Results, HLA, & Testing

Lab Results, HLA, & Testing

HLA Typing
HLA-A
HLA-B
HLA-C
HLA-DRB1
HLA-DRB4
HLA-DQA1
HLA-DQB1
HLA-DPA1
HLA-DPB1
ABO Type
Rh Type
CMV Status
HIV/HBV/HCV Tested
Syphilis Tested
Flow Data

Flow Data

Has Flow Data
Viable CD45+ (% of singlets)
CD3+ T cells (% of viable CD45+)
CD4+CD8− (% of viable CD45+)
CD4−CD8+ (% of viable CD45+)
CD3−CD16/56+ NK (% of viable CD45+)
CD19+ B cells (% of viable CD45+)
CD14+ monocytes (% of viable CD45+)
Lifestyle

Lifestyle

Tobacco Use
Alcohol Use
Recreational Drug Use
Caffeine Use
Find by ID

Find by ID

Lot # / SO#

Start typing to see matching Lot # / SO#.

Patient ID

Start typing to see matching Patient ID.

10 lots match
10 lots available
Specimen IDSample TypeBag SizeCells / VolumePrimary DiseaseDiagnosisAllergiesAllergy ListHas Food AllergiesBMICMV StatusHIV/HBV/HCV TestedSyphilis TestedHas Infectious DiseaseInfectious DiseaseTobacco UseYears of SmokingPacks per DayAlcohol UseRecreational Drug UseCaffeine UseABO TypeRh TypeViable CD45+ (% of singlets)CD3+ T cells (% of viable CD45+)CD4+CD8− (% of viable CD45+)CD4−CD8+ (% of viable CD45+)CD3−CD16/56+ NK (% of viable CD45+)CD19+ B cells (% of viable CD45+)CD14+ monocytes (% of viable CD45+)Sample StatusAvailability
Healthy Leukopak 75615 148960 Male 31-45 Caucasian Cryopreserved, Fresh 100 mL 2 7,475M Vitamin B Fluoxetine Bupropion Minoxidil Fluoxetine Raloxifene Estradiol injections from patches 25mg of Seroquel most nights — United States 2026 A*26:01:01:01/A*32:01:01:01 — — — — — — — — 198031; 198030LeukopakHalf Bag7475M cellsNormal (Healthy)HealthyYesPenicillin, amoxicillin26.25Non ReactiveYesYesNoNoYesYESNoARH+StoredIn Stock
$5,367
Healthy Leukopak 59323 138757 Male 31-45 Caucasian Asian/Pacific Islander Cryopreserved, Fresh 100 mL 1 3,900M Vitamin B12 QW3 — United States 2024 03:01:01:01/03:330N — — — — — — — — 23077LeukopakHalf Bag3900M cellsNormal (Healthy)HealthyNo24.39Non ReactiveYesNoNoNoYesNOARH+StoredIn Stock
$5,367
Healthy Leukopak 74075 137762 Female 18-30 Caucasian Cryopreserved, Fresh 100 mL 2 2,800M Melatonin QD — United States 2026 01:01:01:01/02:01:01:01 — — — — — — — — 195413; 195412LeukopakHalf Bag2800M cellsNormal (Healthy)HealthyNo23.73Non ReactiveYesNoNoNoNoNOYesORH-StoredIn Stock
$5,367
Diabetes Type I Leukopak 55922 139772 Male 46-60 Hispanic/Latino Cryopreserved, Fresh 1 mL 1 3,197M Humalog 125 Units QD Pantoprazole 40 mg QD Losartan 50 mg QD Atorvastatin 40 mg QD Naltrexone 50 mg QD Bupropion 300 mg QD Diabetes Type I United States 2024 — — — — — — — — — 6571LeukopakHalf Bag3197M cellsDiabetes Type IDiabetes Type 1No29.53NoNoNoNoNoNOYesStoredIn Stock
$10,500
Diabetes Type I Leukopak 57651 118114 Female 31-45 Caucasian Cryopreserved, Fresh 1 mL 1 5,000M Humalog/40units / QD, TACEBA 16 U IN MORN/10 AT NIGHT Diabetes Type I United States 2024 02:01:01:01/23:01:01:01 35:02:01G/51:01:01G 04:01:01G/16:01:01G 03:01:01G/13:02:01G — 01:02:01G/05:01:01G 02:01:01G/05:01:01G 01:03:01G/02:07:01G 04:01:01G/85:01:01G 6622LeukopakHalf Bag5000M cellsDiabetes Type IDiabetes Type 1No22.71CMV NegativeYesNoNoNoYesYESYesARH+StoredIn Stock
$10,500
Healthy Leukopak 56090 139468 Male 46-60 Caucasian Hispanic/Latino Cryopreserved, Fresh 100 mL 1 3,607M — — United States 2024 02:01:01G/11:01:01G 35:01:01G/48:01:01G 04:01:01G/08:01:01G 11:01:01G/14:02:01G — 05:01:01G 03:01:01G 01:03:01G 02:01:02G/04:01:01G 6559LeukopakHalf Bag3607M cellsNormal (Healthy)HealthyNo35.62ReactiveYesNoNoYes-Currently Smokes15YesNOYesARH+StoredIn Stock
$5,367
Healthy Leukopak 59170 137689 Female 31-45 Caucasian Cryopreserved, Fresh 140 mL 1 10,010M Evening primrose QD Vitamin D supplement PRN Fluoxetine 20mg — United States 2024 03:01:55/03:330N — — — — — — — — 23057LeukopakFull Bag10010M cellsNormal (Healthy)HealthyYesSeasonal - pollen and dust25.01CMV PositiveYesNoNoYes-Currently Smokes150YesNOYesARH-StoredIn Stock
$7,581
Healthy Leukopak 56021 141074 Male 31-45 Hispanic/Latino Cryopreserved, Fresh 1 mL 2 12,250M No meds or supp — United States 2024 02:01:01:01/68:02:01:01 — — — — — — — — 6550; 6551LeukopakFull Bag12250M cellsNormal (Healthy)HealthyNo31.99CMV PositiveNoNoNoYes-Currently Smokes250.5NoNOYesARH+StoredIn Stock
$7,581
Healthy Leukopak 55994 141417 Female 31-45 Hispanic/Latino Cryopreserved, Fresh 100 mL 2 5,000M Iron QD Vitamin B12 QD Vitamin C QD Collagen QD — United States 2024 11:01:01:01/31:01:02:01 — — — — — — — — 6563; 6564LeukopakHalf Bag5000M cellsNormal (Healthy)HealthyNo30.38Non ReactiveYesNoNoYes-Currently Smokes80.1NoNOYesORH+StoredIn Stock
$5,367
Diabetes Type I Leukopak 59332 AI-3017 Male 31-45 Hispanic/Latino Cryopreserved, Fresh 100 mL 1 9,000M Himalogue pump - based on 1 for every 7 carts None Diabetes Type I United States 2024 02:01:01:01/29:02:01:01 — — — — — — — — 23042LeukopakFull Bag9000M cellsDiabetes Type IDiabetes Type 1No32.28ReactiveYesNoNoNoYesNOYesORH+StoredIn Stock
$15,225

Showing 1–10 of 10 lots

About Human Leukopaks

Human Leukopaks are sourced from consented donors. These samples support immune-cell research, with donor information on condition, demographics, medications and comorbidities.

Applications

  • Immune-cell phenotyping
  • Downstream immune-cell isolation studies
  • Cellular functional assays
  • Translational immunology research

Product Features

  • Human leukopak material
  • Consented donor collection
  • Research Use Only (RUO)

De-identified Donor Data

  • Donor condition/diagnosis and documented clinical phenotype
  • Age, gender and race/ethnicity
  • Medications and comorbidities
  • HLA typing and CMV status
  • HIV, HBV, HCV and syphilis testing
  • ABO/Rh blood type and country of collection
  • Tobacco, alcohol, caffeine and recreational drug use

Processing specifications

Anticoagulant
Confirmed per lot on request
Formats
Cryopreserved, FreshBag sizesFull BagHalf Bag
Processing window
Processed within 24 hours of collection unless otherwise stated
Cryopreservation
Plasma-reduced; serum-free freezing medium with 10% DMSO; controlled-rate freezer
Storage
Vapor-phase liquid nitrogen
Count and viability
Total nucleated cell count and viability by AO/PI on a dual-fluorescence counter

From Sanguine's processing protocols. View protocols

Donor and clinical data in these lots

Fields recorded on the 10 in-stock Leukopak lots, across all conditions. Coverage varies by donor; blank fields are not available for that lot.

Donor

Sex
10 of 10 lots
Age
10 of 10 lots
Race
10 of 10 lots
BMI
10 of 10 lots

Clinical history

Primary diagnosis
10 of 10 lots
Current medications
9 of 10 lots
Allergies
10 of 10 lots
Infectious disease history
10 of 10 lots

Lab results & genotype

CMV serostatus
9 of 10 lots
ABO / Rh blood type
9 of 10 lots
HLA class I typing
9 of 10 lots
HLA class II typing
2 of 10 lots

Lifestyle

Tobacco use
10 of 10 lots
Smoking history
4 of 10 lots
Alcohol use
10 of 10 lots
Recreational drug use
10 of 10 lots
Caffeine use
9 of 10 lots

Collection

Collection date
10 of 10 lots
Country of collection
10 of 10 lots

Need a field that isn't listed, such as disease stage or time since diagnosis?

Protocols & Documentation

  • Leukopak Cryopreservation

    Standard operating procedure for cryopreserving leukopak units with controlled freezing and post-thaw viability targets.

    Download
  • Leukopak Thawing

    Validated thawing workflow for cryopreserved leukopaks to maximize recovery while maintaining sterility and chain of custody.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Leukopak

What is a leukopak?

A leukopak is a leukapheresis product: white blood cells collected from one donor by apheresis, which returns the red blood cells and most of the plasma to the donor. It is enriched for mononuclear cells and holds far more of them than a standard blood draw, so a single donor can supply PBMCs or isolated immune-cell subsets, such as T cells, B cells, NK cells and monocytes, for a whole study. Leukopaks on this page are offered fresh or cryopreserved, as full or half bags.

Where can I find your complete catalog?
How long can samples be stored?

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

What customization options are available?

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Do you offer prospective collections?

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

What is the turnaround time for custom collections?

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

Do you have samples in stock?

YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

What does unique donor mean?

Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

Are samples collected under IRB-approved protocols?

YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

Frequently Asked Questions

×

Ask a Question

Need a custom Leukopak cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information